공시 • Mar 12
Apures Co., Ltd., Annual General Meeting, Mar 31, 2026 Apures Co., Ltd., Annual General Meeting, Mar 31, 2026, at 14:00 Tokyo Standard Time. Location: conference room, 44, hansan-gil, cheongbuk-myeon, gyeonggi-do, pyeongtaek South Korea New Risk • May 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Market cap is less than US$10m (₩5.64b market cap, or US$4.05m). New Risk • Apr 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (₩7.68b market cap, or US$5.42m). 공시 • Mar 08
Apures Co., Ltd., Annual General Meeting, Mar 28, 2025 Apures Co., Ltd., Annual General Meeting, Mar 28, 2025, at 14:00 Tokyo Standard Time. Location: conference room, 44, hansan-gil, cheongbuk-myeon, gyeonggi-do, pyeongtaek South Korea New Risk • Mar 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Market cap is less than US$10m (₩12.9b market cap, or US$9.61m). New Risk • Jul 04
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩18.0b market cap, or US$13.9m). 공시 • Mar 19
Apures Co., Ltd. announced that it has received KRW 2.999998485 billion in funding On March 17, 2021, Apures Co., Ltd. (XKON:A149300) closed the transaction. Is New 90 Day High Low • Mar 11
New 90-day low: ₩2,510 The company is down 26% from its price of ₩3,390 on 11 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 16% over the same period. 공시 • Mar 11
Apures Co., Ltd. announced that it expects to receive KRW 2.999998485 billion in funding Apures Co., Ltd. (XKON:A149300) announced a private placement to issue 1,204,335 shares at a price of KRW 2,491 per share for gross proceeds of KRW 2,999,998,485 to new investor, Genen Bio on March 9, 2021 The face value is KRW 500 per share. The company is raising funding through third party allocation increase method. The transaction is expected to close by March 17, 2021. The transaction has approved by the board of directors of the company. Is New 90 Day High Low • Dec 07
New 90-day high: ₩3,450 The company is up 146% from its price of ₩1,400 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period. Is New 90 Day High Low • Nov 13
New 90-day high: ₩1,950 The company is up 21% from its price of ₩1,610 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. Is New 90 Day High Low • Oct 16
New 90-day high: ₩1,810 The company is up 5.0% from its price of ₩1,730 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 2.0% over the same period. 공시 • Jul 18
Apures Co., Ltd. announced that it has received KRW 2.889 billion in funding from AmWest Funding Corp. On July 14, 2020, Apures Co., Ltd. (XKON:A149300) closed the transaction. 공시 • Jul 17
Apures Co., Ltd. announced that it expects to receive KRW 2.889 billion in funding from AmWest Funding Corp. and another investor Apures Co., Ltd. (XKON:A149300) announced a private placement to issue series 8 non-guaranteed private equity convertible bonds for proceeds of KRW 2,389,000,000 and series 9 registered title of interest-free bond for proceeds of KRW 500,000,000, for aggregate gross proceeds of KRW 2,889,000,000 on July 10, 2020. The transaction will include participation from AmWest Funding Corp. series 8 bonds and M. West Funding Korea for series 9 bonds. The series 8 carry fixed coupon rate of 4% per annum and series 9 bonds have a surface interest rate of 4% and will mature on July 14, 2023. The series 8 bond are fully convertible into 1,242,329 common shares, representing 3.98% of the company and series 9 bonds are fully convertible into 260,010 shares, representing 0.83% of the company at a conversion price of KRW 1,923 per share. The conversion period for both the bonds will start from July 14, 2021 and ends on July 13, 2023. The bonds carry fixed coupon rate of 4% per annum and will mature on July 14, 2023. The series 8 bond are fully convertible into 1,242,329 common shares and series 9 bonds are full convertible into 260,010 common shares representing 0.83% of the company at a conversion price of KRW 1,923 per share. The conversion period will start from July 14, 2021 and ends on July 13, 2023. The transaction is expected to close on July 14, 2020. The transaction has been approved by the board of directors of the company. 